Your browser doesn't support javascript.
loading
Invasive disease potential of Streptococcus pneumoniae serotypes before and after 10-valent pneumococcal conjugate vaccine introduction in a rural area, southern Mozambique.
Massora, Sérgio; Lessa, Fernanda C; Moiane, Benild; Pimenta, Fabiana C; Mucavele, Hélio; Chaúque, Alberto; Cossa, Anélsio; Verani, Jennifer R; Tembe, Nelson; da Gloria Carvalho, Maria; Muñoz-Almagro, Carmen; Sigaúque, Betuel.
Afiliação
  • Massora S; Fundação Manhiça, Centro de Investigação em Saúde da Manhiça (CISM), Maputo, Mozambique. Electronic address: sergio.massora@manhica.net.
  • Lessa FC; Respiratory Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America. Electronic address: dta3@cdc.gov.
  • Moiane B; Fundação Manhiça, Centro de Investigação em Saúde da Manhiça (CISM), Maputo, Mozambique. Electronic address: benild.moiane@manhica.net.
  • Pimenta FC; Respiratory Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America. Electronic address: gzy7@cdc.gov.
  • Mucavele H; Fundação Manhiça, Centro de Investigação em Saúde da Manhiça (CISM), Maputo, Mozambique. Electronic address: helio.mucavele@manhica.net.
  • Chaúque A; Fundação Manhiça, Centro de Investigação em Saúde da Manhiça (CISM), Maputo, Mozambique. Electronic address: alberto.chauque@mahica.net.
  • Cossa A; Fundação Manhiça, Centro de Investigação em Saúde da Manhiça (CISM), Maputo, Mozambique. Electronic address: anelsio.cossa@manhica.net.
  • Verani JR; Respiratory Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America. Electronic address: qzr7@cdc.gov.
  • Tembe N; Fundação Manhiça, Centro de Investigação em Saúde da Manhiça (CISM), Maputo, Mozambique. Electronic address: nelson.tembe@manhica.net.
  • da Gloria Carvalho M; Respiratory Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America. Electronic address: msc8@cdc.gov.
  • Muñoz-Almagro C; Molecular Microbiology Department, Instituto de Recerca Pediatrica, University Hospital Sant Joan de Deu, Barcelona, Spain; Ciber of Epidemiology and Public Health, CIBERESP, Instituto de Salud Carlos III, Madrid, Spain; Medicine Department, Universitat Internacional de Catalunya, Barcelona, Spain.
  • Sigaúque B; Fundação Manhiça, Centro de Investigação em Saúde da Manhiça (CISM), Maputo, Mozambique. Electronic address: betuel.sigauque@manhica.net.
Vaccine ; 37(51): 7470-7477, 2019 12 03.
Article em En | MEDLINE | ID: mdl-31575493
ABSTRACT

BACKGROUND:

Invasive pneumococcal disease (IPD) is a significant cause of morbidity and mortality among children worldwide. In April 2013, Mozambique introduced 10-valent PCV (PCV10) into the National Expanded Program on immunization using a three-dose schedule at 2, 3, and 4 months of age. We aimed to evaluate the invasive disease potential of pneumococcal serotypes among children in our region before and after PCV10 introduction.

METHODS:

We used data from ongoing population-based surveillance for IPD and cross-sectional pneumococcal carriage surveys among children aged <5 years in Manhiҫa, Mozambique. To determine the invasive disease potential for each serotype pre- and post-PCV10 introduction, odds ratios (OR) and 95% confidence intervals (95% CI) were calculated comparing serotype-specific prevalence in IPD and in carriage. For each serotype, OR and 95% CI > 1 indicated high invasive disease potential and OR and 95% CI < 1 indicated low invasive disease potential.

RESULTS:

In the pre-PCV10 period, 524 pneumococcal isolates were obtained from 411 colonized children and IPD cases were detected in 40 children. In the post-PCV10 period, 540 pneumococcal isolates were obtained from 507 colonized children and IPD cases were detected in 30 children. The most prevalent serotypes causing IPD pre-PCV10 were 6A (17.5%), 6B (15.0%), 14 (12.5%), 23F (10.0%) and 19F (7.5%), and post-PCV10 were 6A (36.7%), 13 (10%), 1 (10.0%), 6B (6.7%) and 19A (6.7%). Serotypes associated with high invasive disease potential pre-PCV10 included 1 (OR22.3 [95% CI 2.0; 251.2]), 6B (OR3.1 [95% CI 1.2; 8.1]), 14 (OR 3.4 [95% CI 1.2; 9.8]) and post-PCV10 included serotype 6A (OR6.1[95% CI 2.7; 13.5]).

CONCLUSION:

The number of serotypes with high invasive disease potential decreased after PCV10 introduction. Serotype 6A, which is not included in PCV10, was the most common cause of IPD throughout the study and showed a high invasive potential in the post-PCV10 period.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pneumonia Pneumocócica / Streptococcus pneumoniae / Vacinação / Vacinas Pneumocócicas Tipo de estudo: Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Child, preschool / Female / Humans / Infant / Male / Newborn País como assunto: Africa Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pneumonia Pneumocócica / Streptococcus pneumoniae / Vacinação / Vacinas Pneumocócicas Tipo de estudo: Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Child, preschool / Female / Humans / Infant / Male / Newborn País como assunto: Africa Idioma: En Ano de publicação: 2019 Tipo de documento: Article